The DOI matches its Crossref record; 197 of the 197 references it cites were found in a registry or an index.
IL-12 Family Cytokines in Cancer and Immunotherapy
Open accessAbstract
The IL-12 family cytokines are a group of unique heterodimeric cytokines that include IL-12, IL-23, IL-27, IL-35 and, most recently, IL-39. Recent studies have solidified the importance of IL-12 cytokines in shaping innate and adaptive immune responses in cancer and identified multipronged roles for distinct IL-12 family members, ranging from effector to regulatory immune functions. These cytokines could serve as promising candidates for the development of immunomodulatory therapeutic approaches. Overall, IL-12 can be considered an effector cytokine and has been found to engage anti-tumor immunity by activating the effector Th1 response, which is required for the activation of cytotoxic T and NK cells and tumor clearance. IL-23 and IL-27 play dual roles in tumor immunity, as they can both activate effector immune responses and promote tumor growth by favoring immune suppression. IL-35 is a potent regulatory cytokine and plays a largely pro-tumorigenic role by inhibiting effector T cells. In this review, we summarize the recent findings on IL-12 family cytokines in the control of tumor growth with an emphasis primarily on immune regulation. We underscore the clinical implications for the use of these cytokines either in the setting of monotherapy or in combination with other conventional therapies for the more effective treatment of malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
The inhibitory cytokine IL-35 contributes to regulatory T-cell function
Collison, L. W., Workman, C. J., Kuo, T. T., Boyd, K., Wang, Y., Vignali, K. M., Cross, R., Sehy, D., Blumberg, R. S., & Vignali, D. A. A. (2007) · Nature · doi:10.1038/nature06306 · Cited by 2,066
Molecular Mechanisms That Influence the Macrophage M1–M2 Polarization Balance
Wang, N., Liang, H., & Zen, K. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00614 · Cited by 1,980
The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing
Gaffen, S. L., Jain, R., Garg, A. V., & Cua, D. J. (2014) · Nature reviews. Immunology · doi:10.1038/nri3707 · Cited by 1,585
Adenoma–linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth
Grivennikov, S. I., Wang, K., Mucida, D., Stewart, C. A., Schnabl, B., Jauch, D., Taniguchi, K., Yu, G.-Y., Österreicher, C. H., Hung, K. E., et al. (2012) · Nature · doi:10.1038/nature11465 · Cited by 1,327
IL-12 family cytokines: immunological playmakers
Vignali, D. A. A., & Kuchroo, V. K. (2012) · Nature Immunology · doi:10.1038/ni.2366 · Cited by 1,297
Toxicities of chimeric antigen receptor T cells: recognition and management
Brudno, J. N., & Kochenderfer, J. N. (2016) · Blood · doi:10.1182/blood-2016-04-703751 · Cited by 1,283
The IL-23/IL-17 axis in inflammation
Iwakura, Y. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28508 · Cited by 1,046
IL-23 promotes tumour incidence and growth
Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M. (2006) · Nature · doi:10.1038/nature04808 · Cited by 1,018
Garris, C. S., Arlauckas, S. P., Kohler, R. H., Trefny, M. P., Garren, S., Piot, C., Engblom, C., Pfirschke, C., Siwicki, M., Gungabeesoon, J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.024 · Cited by 966 · cited 1×
“The activation of anti-tumor immunity by anti-PD1 requires IL-12-mediated crosstalk between T cells and dendritic cells that enables CD8+ T cell-mediated tumor cell killing [22].”
BackgroundCommensal Microbiota Promote Lung Cancer Development via γδ T Cells
Jin, C., Lagoudas, G. K., Zhao, C., Bullman, S., Bhutkar, A., Hu, B., Ameh, S., Sandel, D., Liang, X. S., Mazzilli, S., et al. (2019) · Cell · doi:10.1016/j.cell.2018.12.040 · Cited by 964
Li, C., Jiang, P., Wei, S., Xu, X., & Wang, J. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01234-1 · Cited by 921
Toxicity and management in CAR T-cell therapy
Bonifant, C. L., Jackson, H. J., Brentjens, R. J., & Curran, K. J. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.11 · Cited by 885
Wang, X.-Y., Richter, M., He, Y., Björk, J., Riss, A., Rajesh, R., Garnica, M., Hennersdorf, F., Weigand, J. J., Narita, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01934-1 · Cited by 883
IL-35-mediated induction of a potent regulatory T cell population
Collison, L. W., Chaturvedi, V., Henderson, A. L., Giacomin, P. R., Guy, C., Bankoti, J., Finkelstein, D., Forbes, K., Workman, C. J., Brown, S. A., et al. (2010) · Nature Immunology · doi:10.1038/ni.1952 · Cited by 869
IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway
Wang, L., Yi, T., Kortylewski, M., Pardoll, D. M., Zeng, D., & Yu, H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090207 · Cited by 842
Leonard, J. P., Sherman, M. L., Fisher, G. L., Buchanan, L. J., Larsen, G., Atkins, M. B., Sosman, J. A., Dutcher, J. P., Vogelzang, N. J., & Ryan, J. L. (1997) · PubMed · Cited by 820
Feng, D., Wang, K., Wei, Z., Chen, Y.-P., Simon, C. M., Arvapally, R. K., Martin, R. L., Bosch, M., Liu, T.-F., Fordham, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms7106 · Cited by 789
Kastelein, R. A., Hunter, C. A., & Cua, D. J. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104758 · Cited by 763
Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability
Lee, J. S., Tato, C. M., Joyce-Shaikh, B., Gulen, M. F., Cayatte, C., Chen, Y., Blumenschein, W. M., Judo, M., Ayanoglu, G., McClanahan, T. K., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.09.003 · Cited by 760
Interleukin-35 induces regulatory B cells that suppress autoimmune disease
Wang, R.-X., Yu, C.-R., Dambuza, I. M., Mahdi, R. M., Dolinska, M. B., Sergeev, Y. V., Wingfield, P. T., Kim, S.-H., & Egwuagu, C. E. (2014) · Nature Medicine · doi:10.1038/nm.3554 · Cited by 733
Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis
Hawkes, J. E., Yan, B. Y., Chan, T. C., & Krueger, J. G. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800013 · Cited by 593
Niedbala, W., Wei, X., Cai, B., Hueber, A. J., Leung, B. P., McInnes, I. B., & Liew, F. Y. (2007) · European Journal of Immunology · doi:10.1002/eji.200737810 · Cited by 588
New insights into IL-12-mediated tumor suppression
Tugues, S., Burkhard, S. H., Ohs, I., Vrohlings, M., Nussbaum, K., vom Berg, J., Kulig, P., & Becher, B. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.134 · Cited by 558
Myc Cooperates with Ras by Programming Inflammation and Immune Suppression
Kortlever, R. M., Sodir, N. M., Wilson, C. H., Burkhart, D. L., Pellegrinet, L., Brown Swigart, L., Littlewood, T. D., & Evan, G. I. (2017) · Cell · doi:10.1016/j.cell.2017.11.013 · Cited by 553
Ibáñez-Sanz, G., Díez-Villanueva, A., Alonso, M. H., Rodríguez-Moranta, F., Pérez-Gómez, B., Bustamante, M., Martin, V., Llorca, J., Amiano, P., Ardanaz, E., et al. (2017) · Scientific Reports · doi:10.1038/srep46807 · Cited by 505
Direct visualization of current-induced spin accumulation in topological insulators
Liu, Y., Besbas, J., Wang, Y., He, P., Chen, M., Zhu, D., Wu, Y., Lee, J. M., Wang, L., Moon, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04939-6 · Cited by 497
The Effects of Cold and Lower Body Negative Pressure on Cardiovascular Homeostasis
Kean, D. J., Peacock, C. A., Sanders, G. J., McDaniel, J., Colvin, L. A. C., & Glickman, E. L. (2015) · BioMed Research International · doi:10.1155/2015/728145 · Cited by 492
The Immunobiology of the Interleukin-12 Family: Room for Discovery
Tait Wojno, E. D., Hunter, C. A., & Stumhofer, J. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.011 · Cited by 482
Pot, C., Jin, H., Awasthi, A., Liu, S. M., Lai, C.-Y., Madan, R., Sharpe, A. H., Karp, C. L., Miaw, S.-C., Ho, I.-C., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901233 · Cited by 467
Mechanisms regulating PD-L1 expression on tumor and immune cells
Chen, S., Crabill, G. A., Pritchard, T. S., McMiller, T. L., Wei, P., Pardoll, D. M., Pan, F., & Topalian, S. L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0770-2 · Cited by 459
The composition and signaling of the IL-35 receptor are unconventional
Collison, L. W., Delgoffe, G. M., Guy, C. S., Vignali, K. M., Chaturvedi, V., Fairweather, D., Satoskar, A. R., Garcia, K. C., Hunter, C. A., Drake, C. G., et al. (2012) · Nature Immunology · doi:10.1038/ni.2227 · Cited by 450
Localized Interleukin-12 for Cancer Immunotherapy
Nguyen, K. G., Vrabel, M. R., Mantooth, S. M., Hopkins, J. J., Wagner, E. S., Gabaldon, T. A., & Zaharoff, D. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.575597 · Cited by 431
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo
Koneru, M., Purdon, T. J., Spriggs, D., Koneru, S., & Brentjens, R. J. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.994446 · Cited by 418
The significance of exosomes in the development and treatment of hepatocellular carcinoma
Li, X., Li, C., Zhang, L., Wu, M., Cao, K., Jiang, F., Chen, D., Li, N., & Li, W. (2020) · Molecular Cancer · doi:10.1186/s12943-019-1085-0 · Cited by 395
Il-23 secreted by myeloid cells drives castration-resistant prostate cancer
Calcinotto, A., Spataro, C., Zagato, E., Di Mitri, D., Gil, V., Crespo, M., De Bernardis, G., Losa, M., Mirenda, M., Pasquini, E., et al. (2018) · Nature · doi:10.1038/s41586-018-0266-0 · Cited by 394
Lazarevic, V., Chen, X., Shim, J.-H., Hwang, E.-S., Jang, E., Bolm, A. N., Oukka, M., Kuchroo, V. K., & Glimcher, L. H. (2011) · Nature Immunology · doi:10.1038/ni.1969 · Cited by 385
Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy
Vilgelm, A. E., & Richmond, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00333 · Cited by 379
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
Kerkar, S. P., Goldszmid, R. S., Muranski, P., Chinnasamy, D., Yu, Z., Reger, R. N., Leonardi, A. J., Morgan, R. A., Wang, E., Marincola, F. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58814 · Cited by 342
Wang, K., Kim, M. K., Di Caro, G., Wong, J., Shalapour, S., Wan, J., Zhang, W., Zhong, Z., Sanchez-Lopez, E., Wu, L.-W., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.11.009 · Cited by 341
Th17 Cells in Cancer: The Ultimate Identity Crisis
Bailey, S. R., Nelson, M. H., Himes, R. A., Li, Z., Mehrotra, S., & Paulos, C. M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00276 · Cited by 334
Interleukin-35 Limits Anti-Tumor Immunity
Turnis, M. E., Sawant, D. V., Szymczak-Workman, A. L., Andrews, L. P., Delgoffe, G. M., Yano, H., Beres, A. J., Vogel, P., Workman, C. J., & Vignali, D. A. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.013 · Cited by 311
Chinnasamy, D., Yu, Z., Kerkar, S. P., Zhang, L., Morgan, R. A., Restifo, N. P., & Rosenberg, S. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3050 · Cited by 277
IL-27 Is a Key Regulator of IL-10 and IL-17 Production by Human CD4+ T Cells
Murugaiyan, G., Mittal, A., Lopez-Diego, R., Maier, L. M., Anderson, D. E., & Weiner, H. L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900568 · Cited by 276
IL-17A Produced by γδ T Cells Promotes Tumor Growth in Hepatocellular Carcinoma
Ma, S., Cheng, Q., Cai, Y., Gong, H., Wu, Y., Yu, X., Shi, L., Wu, D., Dong, C., & Liu, H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2534 · Cited by 264
The good and the bad faces of STAT1 in solid tumours
Meissl, K., Macho-Maschler, S., Müller, M., & Strobl, B. (2017) · Cytokine · doi:10.1016/j.cyto.2015.11.011 · Cited by 264
Chiocca, E. A., Yu, J. S., Lukas, R. V., Solomon, I. H., Ligon, K. L., Nakashima, H., Triggs, D. A., Reardon, D. A., Wen, P., Stopa, B. M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw5680 · Cited by 263
Th17 Cell Plasticity and Functions in Cancer Immunity
Guéry, L., & Hugues, S. (2015) · BioMed Research International · doi:10.1155/2015/314620 · Cited by 261
Kerkar, S. P., Muranski, P., Kaiser, A., Boni, A., Sanchez-Perez, L., Yu, Z., Palmer, D. C., Reger, R. N., Borman, Z. A., Zhang, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0735 · Cited by 254
Interleukin-23 engineering improves CAR T cell function in solid tumors
Ma, X., Shou, P., Smith, C., Chen, Y., Du, H., Sun, C., Porterfield Kren, N., Michaud, D., Ahn, S., Vincent, B., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0398-2 · Cited by 253
Self-citationJenner, R. G., Townsend, M. J., Jackson, I., Sun, K., Bouwman, R. D., Young, R. A., Glimcher, L. H., & Lord, G. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909357106 · Cited by 251
Potent Antitumor Activity of Interleukin-27
Hisada, M., Kamiya, S., Fujita, K., Belladonna, M. L., Aoki, T., Koyanagi, Y., Mizuguchi, J., & Yoshimoto, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2084 · Cited by 244
Thieu, V. T., Yu, Q., Chang, H.-C., Yeh, N., Nguyen, E. T., Sehra, S., & Kaplan, M. H. (2008) · Immunity · doi:10.1016/j.immuni.2008.08.017 · Cited by 231
Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment
Hewitt, S. L., Bailey, D., Zielinski, J., Apte, A., Musenge, F., Karp, R., Burke, S., Garcon, F., Mishra, A., Gurumurthy, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0472 · Cited by 227
Kamiya, S., Owaki, T., Morishima, N., Fukai, F., Mizuguchi, J., & Yoshimoto, T. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.3871 · Cited by 220
IL-27 Limits IL-2 Production during Th1 Differentiation
Villarino, A. V., Stumhofer, J. S., Saris, C. J. M., Kastelein, R. A., de Sauvage, F. J., & Hunter, C. A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.237 · Cited by 216
Regulation of interleukin-12 production in antigen-presenting cells
Mal, X., & Trinchieri, G. (2001) · Advances in Immunology · doi:10.1016/s0065-2776(01)79002-5 · Cited by 214
IL-23 in inflammatory bowel diseases and colon cancer
Neurath, M. F. (2019) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.12.002 · Cited by 214
Interleukin-12: Functional activities and implications for disease
Zundler, S., & Neurath, M. F. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.07.003 · Cited by 212
Fu, Q., Xu, L., Wang, Y., Jiang, Q., Liu, Z., Zhang, J., Zhou, Q., Zeng, H., Tong, S., Wang, T., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.09.030 · Cited by 211
JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation
Gotthardt, D., Trifinopoulos, J., Sexl, V., & Putz, E. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02590 · Cited by 211
Interleukin-35 Mediates Mucosal Immune Responses That Protect Against T-Cell–Dependent Colitis
Wirtz, S., Billmeier, U., Mchedlidze, T., Blumberg, R. S., & Neurath, M. F. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.040 · Cited by 207
An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction
Zhu, C., Sakuishi, K., Xiao, S., Sun, Z., Zaghouani, S., Gu, G., Wang, C., Tan, D. J., Wu, C., Rangachari, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms7072 · Cited by 206
A Role for IL-27 in Early Regulation of Th1 Differentiation
Owaki, T., Asakawa, M., Morishima, N., Hata, K., Fukai, F., Matsui, M., Mizuguchi, J., & Yoshimoto, T. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2191 · Cited by 203
Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications
Testa, U., Castelli, G., & Pelosi, E. (2019) · Medicines · doi:10.3390/medicines6030082 · Cited by 194
Hirahara, K., Onodera, A., Villarino, A. V., Bonelli, M. M., Sciumè, G., Laurence, A. D. J., Sun, H., Brooks, S. R., Vahedi, G., Shih, H., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.04.014 · Cited by 184
Kueberuwa, G., Kalaitsidou, M., Cheadle, E., Hawkins, R. E., & Gilham, D. E. (2018) · Molecular Therapy - Oncolytics · doi:10.1016/j.omto.2017.12.003 · Cited by 179
Dambuza, I. M., He, C., Choi, J. K., Yu, C.-R., Wang, R., Mattapallil, M. J., Wingfield, P. T., Caspi, R. R., & Egwuagu, C. E. (2017) · Nature Communications · doi:10.1038/s41467-017-00838-4 · Cited by 177
A novel IL‐23p19/Ebi3 (IL‐39) cytokine mediates inflammation in Lupus‐like mice
Wang, X., Wei, Y., Xiao, H., Liu, X., Zhang, Y., Han, G., Chen, G., Hou, C., Ma, N., Shen, B., et al. (2016) · European Journal of Immunology · doi:10.1002/eji.201546095 · Cited by 175
Wang, P., Li, X., Wang, J., Gao, D., Li, Y., Li, H., Chu, Y., Zhang, Z., Liu, H., Jiang, G., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01385-8 · Cited by 174
Induction of regulatory Tr1 cells and inhibition of TH17 cells by IL-27
Pot, C., Apetoh, L., Awasthi, A., & Kuchroo, V. K. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.08.003 · Cited by 165
Pan, B., Shen, J., Cao, J., Zhou, Y., Shang, L., Jin, S., Cao, S., Che, D., Liu, F., & Yu, Y. (2015) · Scientific Reports · doi:10.1038/srep16053 · Cited by 165
Tumor-Derived IL-35 Promotes Tumor Growth by Enhancing Myeloid Cell Accumulation and Angiogenesis
Wang, Z., Liu, J.-Q., Liu, Z., Shen, R. Z., Zhang, G., Xu, J., Basu, S., Feng, Y., & Bai, X. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202535 · Cited by 163
Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer
Yan, J., Smyth, M. J., & Teng, M. W. L. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028530 · Cited by 161
Allen, F., Bobanga, I., Rauhe, P., Barkauskas, D. S., Teich, N., Tong, C., Myers, J., & Huang, A. Y.-C. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1393598 · Cited by 159
Lee, C.-C., Lin, J.-C., Hwang, W., Kuo, Y., Chen, H.-K., Tai, S., Lin, C., & Yang, M. (2018) · Nature Communications · doi:10.1038/s41467-018-06268-0 · Cited by 158
Zwirner, N. W., & Ziblat, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00025 · Cited by 150
Liu, Y., Di, S., Shi, B., Zhang, H., Wang, Y., Wu, X., Luo, H., Wang, H., Li, Z., & Jiang, H. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800033 · Cited by 150
IL-27 induces the expression of IDO and PD-L1 in human cancer cells
Carbotti, G., Barisione, G., Airoldi, I., Mezzanzanica, D., Bagnoli, M., Ferrero, S., Petretto, A., Fabbi, M., & Ferrini, S. (2015) · Oncotarget · doi:10.18632/oncotarget.6530 · Cited by 149
Zhang, T., Qu, R., Chan, S., Lai, M., Tong, L., Fěng, F., Chen, H., Song, T., Song, P., Bai, G., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01202-9 · Cited by 149
Schneider, R., Yaneva, T., Beauseigle, D., El‐Khoury, L., & Arbour, N. (2010) · European Journal of Immunology · doi:10.1002/eji.201040804 · Cited by 146
Chang, K., Liu, L.-B., Jin, L., Zhang, B., Mei, J., Li, H., Wei, C.-Y., Zhou, W., Zhu, X., Shao, J., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.95 · Cited by 145
Hasegawa, H., Mizoguchi, I., Chiba, Y., Ohashi, M., Xu, M., & Yoshimoto, T. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00479 · Cited by 142
Differential Effects of IL-12 on Tregs and Non-Treg T Cells: Roles of IFN-γ, IL-2 and IL-2R
Zhao, J., Zhao, J., & Perlman, S. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046241 · Cited by 142
Dual Roles of IL-27 in Cancer Biology and Immunotherapy
Fabbi, M., Carbotti, G., & Ferrini, S. (2017) · Mediators of Inflammation · doi:10.1155/2017/3958069 · Cited by 142
Mao, Z., Zhang, J., Shi, Y., Li, W., Shi, H., Ji, R., Mao, F., Qian, H., Xu, W., & Zhang, X. (2020) · Oncogenesis · doi:10.1038/s41389-020-00249-z · Cited by 142
Horlad, H., Ma, C., Yano, H., Pan, C., Ohnishi, K., Fujiwara, Y., Endo, S., Kikukawa, Y., Okuno, Y., Matsuoka, M., et al. (2016) · Cancer Science · doi:10.1111/cas.13065 · Cited by 141
Huang, C., Li, N., Li, Z., Chang, A., Chen, Y., Zhao, T., Li, Y., Wang, X., Zhang, W., Wang, Z., et al. (2017) · Nature Communications · doi:10.1038/ncomms14035 · Cited by 141
IL-27 Suppresses CD28-Medicated IL-2 Production through Suppressor of Cytokine Signaling 3
Owaki, T., Asakawa, M., Kamiya, S., Takeda, K., Fukai, F., Mizuguchi, J., & Yoshimoto, T. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.5.2773 · Cited by 138
Guzzo, C., Mat, N. F. C., & Gee, K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.112599 · Cited by 136
B cell–Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer
Mirlekar, B., Michaud, D. E., Lee, S. J., Kren, N. P., Harris, C., Greene, K. G., Goldman, E. C., Gupta, G. P., Fields, R. C., Hawkins, W. G., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0349 · Cited by 131
Self-citationInterleukin-27 in T Cell Immunity
Iwasaki, Y., Fujio, K., Okamura, T., & Yamamoto, K. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16022851 · Cited by 127
IL-27 enhances IL-15/IL-18-mediated activation of human natural killer cells
Choi, Y. H., Lim, E. J., Kim, S. W., Moon, Y. W., Park, K. S., & An, H. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0652-7 · Cited by 116
Bekaii‐Saab, T., Roda, J. M., Guenterberg, K. D., Ramaswamy, B., Young, D. C., Ferketich, A. K., Lamb, T., Grever, M. R., Shapiro, C. L., & Carson, W. E. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0820 · Cited by 113
mTOR Mediates IL-23 Induction of Neutrophil IL-17 and IL-22 Production
Chen, F., Cao, A., Yao, S., Evans‐Marin, H., Liu, H., Wu, W. H., Carlsen, E. D., Dann, S. M., Soong, L., Sun, J., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501541 · Cited by 112
Epithelial IL-23R Signaling Licenses Protective IL-22 Responses in Intestinal Inflammation
Aden, K., Rehman, A., Falk‐Paulsen, M., Sécher, T., Kuiper, J. W., Tran, F., Pfeuffer, S., Sheibani‐Tezerji, R., Breuer, A., Luzius, A., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.054 · Cited by 112
Human tolerogenic dendritic cells produce IL‐35 in the absence of other IL‐12 family members
Dixon, K. O., van der Kooij, S. W., Vignali, D. A. A., & van Kooten, C. (2015) · European Journal of Immunology · doi:10.1002/eji.201445217 · Cited by 110
Kunert, A., Chmielewski, M. M., Wijers, R., Berrevoets, C., Abken, H., & Debets, R. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1378842 · Cited by 110
Decoding IL-23 Signaling Cascade for New Therapeutic Opportunities
Pastor-Fernández, G., Mariblanca, I. R., & Navarro, M. N. (2020) · Cells · doi:10.3390/cells9092044 · Cited by 108
Hao, S., Chen, X., Wang, F., Shao, Q., Liu, J., Zhao, H., Yuan, C., Ren, H., & Mao, H. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy136 · Cited by 102
IL-23R–activated STAT3/STAT4 is essential for Th1/Th17-mediated CNS autoimmunity
Lee, P. W., Smith, A. J., Yang, Y., Selhorst, A. J., Liu, Y., Racke, M. K., & Lovett‐Racke, A. E. (2017) · JCI Insight · doi:10.1172/jci.insight.91663 · Cited by 101
Liu, J.-Q., Liu, Z., Zhang, X., Shi, Y., Talebian, F., Carl, J. W., Chuan, Y., Shi, F., Whitacre, C. C., Trgovcich, J., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1100106 · Cited by 99
Liu, Y., Song, Y., Lin, D., Lei, L., Mei, Y., Jin, Z., Gong, H., Zhu, Y., Hu, B., Zhang, Y., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.050 · Cited by 97
Cao, X., Leonard, K., Collins, L. I., Cai, S. F., Mayer, J. C., Payton, J. E., Walter, M. J., Piwnica-Worms, D. R., Schreiber, R. D., & Ley, T. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1145 · Cited by 96
Revisiting Interleukin-12 as a Cancer Immunotherapy Agent
Berraondo, P., Etxeberría, I., Ponz‐Sarvisé, M., & Melero, I. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0381 · Cited by 96
IL-27 in tumor immunity and immunotherapy
Murugaiyan, G., & Saha, B. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.12.002 · Cited by 95
IL-35 induces N2 phenotype of neutrophils to promote tumor growth
Zou, J.-M., Qin, J., Li, Y., Wang, Y., Li, D., Shu, Y., Luo, C., Wang, S., Chi, G., Guo, F., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16819 · Cited by 95
Zhang, J., Lin, Y., Li, C., Zhang, X., Cheng, L., Dai, L., Wang, Y., Wang, F., Shi, G., Li, Y., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600446 · Cited by 94
Mills, B. N., Connolly, K. A., Ye, J., Murphy, J. D., Uccello, T. P., Han, B. J., Zhao, T., Drage, M. G., Murthy, A., Qiu, H., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.095 · Cited by 91
Li, J., Lau, G. K. K., Chen, L., Yuan, Y., Huang, J. C., Luk, J. M., Xie, D., & Guan, X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046264 · Cited by 90
Chronic Inflammation in Skin Malignancies
Tang, L., & Wang, K. (2016) · Journal of Molecular Signaling · doi:10.5334/1750-2187-11-2 · Cited by 86
Koh, J., Kim, H. Y., Lee, Y., Park, I. K., Kang, C. H., Kim, Y. T., Kim, J.-E., Choi, M., Lee, W., Jeon, Y. K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3458 · Cited by 86
Qian, X., Gu, L., Ning, H., Zhang, Y., Hsueh, E. C., Fu, M., Hu, X., Wei, L., Hoft, D. F., & Liu, J. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203141 · Cited by 81
CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment
Martinenaite, E., Ahmad, S. M., Hansen, M., Met, Ö., Westergaard, M. C. W., Larsen, S. K., Klausen, T. W., Donia, M., Svane, I. M., & Andersen, M. H. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1238541 · Cited by 81
Wu, X., Yang, T., Liu, X., Guo, J. N., Xie, T., Ding, Y.-W., Lin, M., & Yang, H. (2015) · Tumor Biology · doi:10.1007/s13277-015-4372-4 · Cited by 80
Nicholl, M. B., Ledgewood, C. L., Chen, X., Bai, Q., Qin, C., Cook, K. M., Herrick, E. J., Diaz‐Arias, A. A., Moore, B. J., & Fang, Y. (2014) · Cytokine · doi:10.1016/j.cyto.2014.06.020 · Cited by 79
Hu, J., Sun, C., Bernatchez, C., Xia, X., Hwu, P., Dotti, G., & Li, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1365 · Cited by 76
Ye, J., Huang, Y., Que, B., Chang, C. C., Liu, W., Hu, H., Liu, L., Shi, Y., Wang, Y., Wang, M., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.06.009 · Cited by 76
Nie, W., Yu, T., Sang, Y., & Gao, X. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.12.048 · Cited by 74
IL-27 confers a protumorigenic activity of regulatory T cells via CD39
Park, Y.-J., Ryu, H., Choi, G., Kim, B. S., Hwang, E. S., Kim, H. S., & Chung, Y. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810254116 · Cited by 74
D'Almeida, S. M., Kauffenstein, G., Roy, C., Basset, L., Papargyris, L., Henrion, D., Catros, V., Ifrah, N., Descamps, P., Croué, A., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1178025 · Cited by 72
Oka, N., Markova, T., Tsuzuki, K., Li, W., El‐Darawish, Y., Pencheva-Demireva, M., Yamanishi, K., Yamanishi, H., Sakagami, M., Tanaka, Y., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02553-4 · Cited by 71
Involvement of CCR6/CCL20/IL-17 Axis in NSCLC Disease Progression
Kirshberg, S., Izhar, U., Amir, G., Demma, J. A., Vernea, F., Beider, K., Shlomai, Z., Wald, H., Zamir, G. A., Shapira, O. M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024856 · Cited by 70
IL-23 and PSMA-targeted duo-CAR T cells in Prostate Cancer Eradication in a preclinical model
Wang, D., Shao, Y., Zhang, X., Lu, G., & Liu, B. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-019-02206-w · Cited by 70
Mirlekar, B., Michaud, D. E., Searcy, R., Greene, K., & Pylayeva‐Gupta, Y. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0710 · Cited by 68
Self-citationMorishima, N., Mizoguchi, I., Okumura, M., Chiba, Y., Xu, M., Shimizu, M., Matsui, M., Mizuguchi, J., & Yoshimoto, T. (2010) · BioMed Research International · doi:10.1155/2010/605483 · Cited by 66
Selected Cytokines in Patients with Pancreatic Cancer: A Preliminary Report
Błogowski, W., Deskur, A., Budkowska, M., Sałata, D., Madej-Michniewicz, A., Dąbkowski, K., Dołęgowska, B., & Starzyñska, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097613 · Cited by 66
Wang, X., Liu, X., Zhang, Y., Wang, Z., Zhu, G., Han, G., Chen, G., Hou, C., Wang, T., Ma, N., et al. (2016) · Clinical & Experimental Immunology · doi:10.1111/cei.12840 · Cited by 66
Fallon, J. K., Vandeveer, A. J., Schlom, J., & Greiner, J. W. (2017) · Oncotarget · doi:10.18632/oncotarget.16137 · Cited by 66
IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy
Zhu, J., Liu, J.-Q., Shi, M., Cheng, X., Ding, M., Zhang, J. C., Davis, J. P., Varikuti, S., Satoskar, A. R., Lu, L., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98745 · Cited by 65
Regulatory T cells‐derived IL ‐35 promotes the growth of adult acute myeloid leukemia blasts
Tao, Q., Pan, Y., Wang, Y., Wang, H., Xiong, S., Li, Q., Wang, J., Tao, L., Wang, Z., Wu, F., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29563 · Cited by 64
Diaz-Montero, C. M., El-Naggar, S. A., Khami, A. A., Naggar, R. A. R. E., Montero, A. J., Cole, D. J., & Salem, M. L. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0394-0 · Cited by 63
Zhang, Q., Liu, S., Zhang, Q., Xiong, Z., Wang, A. R., Myers, L., Melamed, J., Tang, W. W., & You, Z. (2014) · The Prostate · doi:10.1002/pros.22805 · Cited by 63
Sun, R., Hedl, M., & Abraham, C. (2019) · Gut · doi:10.1136/gutjnl-2018-316830 · Cited by 63
Ma, Y., Chen, L., Xie, G., Zhou, Y., Yue, C., Yuan, X., Zheng, Y., Wang, W., Deng, L., & Shen, L. (2016) · Oncotarget · doi:10.18632/oncotarget.12193 · Cited by 62
Molecular Pathways in the Induction of Interleukin-27-Driven Regulatory Type 1 Cells
Pot, C., Apétoh, L., Awasthi, A., & Kuchroo, V. K. (2010) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2010.0047 · Cited by 59
Innate lymphoid cells in tissue homeostasis and diseases
Ignácio, A., Breda, C. N. D. S., & Câmara, N. O. S. (2017) · World Journal of Hepatology · doi:10.4254/wjh.v9.i23.979 · Cited by 59
Circulating IL-35 in pancreatic ductal adenocarcinoma patients
Jin, P., Ren, H., Sun, W., Xin, W., Zhang, H., & Hao, J. (2013) · Human Immunology · doi:10.1016/j.humimm.2013.09.018 · Cited by 58
The IL-23 to IL-17 cascade inflammation-related cancers.
Wang, K., & Karin, M. (2015) · PubMed · Cited by 58
O’Malley, J. T., Sehra, S., Thieu, V. T., Yu, Q., Chang, H., Stritesky, G. L., Nguyen, E., Mathur, A. N., Levy, D. E., & Kaplan, M. H. (2008) · Immunology · doi:10.1111/j.1365-2567.2008.03037.x · Cited by 57
IL-35-producing B cells in gastric cancer patients
Wang, K., Liu, J., & Li, J. (2018) · Medicine · doi:10.1097/md.0000000000010710 · Cited by 56
Targeting interleukin-22 for cancer therapy
Markota, A., Endres, S., & Kobold, S. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1461300 · Cited by 55
Li, J., Zhang, L., Zhang, J., Wei, Y., Li, K., Huang, L., Zhang, S., Gao, B., Wang, X., & Lin, P. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs384 · Cited by 54
Human neutrophils activated via TLR8 promote Th17 polarization through IL-23
Tamassia, N., Arruda-Silva, F., Wright, H. L., Moots, R. J., Gardiman, E., Bianchetto-Aguilera, F. M., Gasperini, S., Capone, M., Maggi, L., Annunziato, F., et al. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.ma0818-308r · Cited by 53
Eckert, F., Jelas, I., Oehme, M., Huber, S. M., Sonntag, K., Welker, C., Gillies, S. D., Strittmatter, W., Zips, D., Handgretinger, R., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1323161 · Cited by 52
Zhang, J., Ji, C., Li, W., Mao, Z., Shi, Y., Shi, H., Ji, R., Qian, H., Xu, W., & Zhang, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00788 · Cited by 52
Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells
Cocco, C., Canale, S., Frasson, C., Carlo, E. D., Ognio, E., Ribatti, D., Prigione, I., Basso, G., & Airoldi, I. (2010) · Blood · doi:10.1182/blood-2009-10-248245 · Cited by 50
Interleukin-35 as an Emerging Player in Tumor Microenvironment
Xue, W., Yan, D., & Kan, Q. (2019) · Journal of Cancer · doi:10.7150/jca.29170 · Cited by 46
Lin, Z., Wu, L.-X., Xie, Y., Ou, X., Tian, P., Liu, X., Min, J., Wang, J., Chen, R., Chen, Y., et al. (2014) · International Journal of Medical Sciences · doi:10.7150/ijms.8352 · Cited by 44
Williams, C. L., Schilling, M. M., Cho, S. H., Lee, K., Wei, M., Aditi, A., & Boothby, M. R. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203360 · Cited by 44
Yao, L., Wang, M., Niu, Z., Liu, Q., Gao, X., Zhou, L., Liao, Q., & Zhao, Y. (2016) · Cytokine · doi:10.1016/j.cyto.2015.12.003 · Cited by 44
Molecular Pathways: Interleukin-35 in Autoimmunity and Cancer
Pylayeva‐Gupta, Y. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0743 · Cited by 44
Self-citationRegulation of the class II and class I MHC pathways in human THP-1 monocytic cells by interleukin-27
Feng, X. M., Liu, N., Yang, S. G., Hu, L. Y., Chen, X., Fang, Z. H., Ren, Q., Lu, S., Liu, B., & Han, Z. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.12.154 · Cited by 42
Haller, S., Duval, A., Migliorini, R., Stevanin, M., Mack, V., & Acha‐Orbea, H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00098 · Cited by 42
Allen, F., Rauhe, P., Askew, D., Tong, A. A., Nthale, J. M., Eid, S. K., Myers, J., Tong, C., & Huang, A. Y.-C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01390 · Cited by 42
The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer
McCuaig, S., Barras, D., Mann, E. H., Friedrich, M., Bullers, S. J., Janney, A., Garner, L. C., Domingo, E., Koelzer, V. H., Delorenzi, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1086 · Cited by 42
IL-23 promotes growth and proliferation in human squamous cell carcinoma of the oral cavity
Fukuda (2010) · International Journal of Oncology · doi:10.3892/ijo_00000620 · Cited by 41
IL-35 expression in hepatocellular carcinoma cells is associated with tumor progression
Long, J., Guo, H.-Y., Cui, S., Zhang, H., Liu, X., Li, D., Han, Z., Xi, L., Kou, W., Xu, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10141 · Cited by 41
IL ‐17A‐producing CD 30+ Vδ1 T cells drive inflammation‐induced cancer progression
Kimura, Y., Nagai, N., Tsunekawa, N., Sato‐Matsushita, M., Yoshimoto, T., Cua, D. J., Iwakura, Y., Yagita∥, H., Okada, F., Tahara, H., et al. (2016) · Cancer Science · doi:10.1111/cas.13005 · Cited by 40
Zhang, T., Song, X., Zhang, Z., Mao, Q., Xia, W., Xu, L., Jiang, F., & Dong, G. (2020) · Oncogenesis · doi:10.1038/s41389-020-00277-9 · Cited by 39
Floss, D. M., Schönberg, M., Franke, M., Horstmeier, F. C., Engelowski, E., Schneider, A., Rosenfeldt, E. M., & Scheller, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-15173-3 · Cited by 38
Aberrant expression of IL-23/IL-23R in patients with breast cancer and its clinical significance
Sheng, S., Zhang, J., Ai, J., Hao, X., & Luan, R. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8427 · Cited by 38
Airoldi, I., Tupone, M. G., Esposito, S., Russo, M. V., Barbarito, G., Cipollone, G., & Carlo, E. D. (2015) · Oncotarget · doi:10.18632/oncotarget.2797 · Cited by 36
Elevated IL-35 in bone marrow of the patients with acute myeloid leukemia
Wang, J., Tao, Q., Wang, H., Wang, Z., Wu, F., Pan, Y., Tao, L., Xiong, S., Wang, Y., & Zhai, Z. (2015) · Human Immunology · doi:10.1016/j.humimm.2015.09.020 · Cited by 33
Chiba, Y., Mizoguchi, I., Furusawa, J.-I., Hasegawa, H., Ohashi, M., Xu, M., Owaki, T., & Yoshimoto, T. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0960 · Cited by 33
Chang, H.-H., Young, S. H., Sinnett‐Smith, J. W., Chou, C. E. N., Moro, A., Hertzer, K. M., Hines, O. J., Rozengurt, E., & Eibl, G. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00417.2014 · Cited by 31
Zhou, W., Chang, K., Wu, K., Yang, H., Mei, J., Xie, F., Li, D., & Li, M. (2017) · Neoplasia · doi:10.1016/j.neo.2017.11.003 · Cited by 29
IL-27 Regulated CD4+IL-10+ T Cells in Experimental Sjögren Syndrome
Qi, J., Zhang, Z., Tang, X., Li, W., Chen, W., & Yao, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01699 · Cited by 29
Chen, G., Liang, Y., Guan, X., Chen, H., Liu, Q., Lin, B., Chen, C., Huang, M., Chen, J., Wu, W., et al. (2016) · PubMed Central · Cited by 28
Carbotti, G., Nikpoor, A. R., Vacca, P., Gangemi, R. M. R., Giordano, C., Campelli, F., Ferrini, S., & Fabbi, M. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0608-z · Cited by 28
Evidence for IL-35 Expression in Diffuse Large B-Cell Lymphoma and Impact on the Patient's Prognosis
Larousserie, F., Kebe, D., Huynh, T., Audebourg, A., Tamburini, J., Terris, B., & Devergne, O. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00563 · Cited by 26
Hu, A., Ding, M., Zhu, J., Liu, J.-Q., Pan, X. J., Ghoshal, K., & Bai, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00210 · Cited by 26
IL-39 acts as a friend to pancreatic cancer
Manning, A. A., Zhao, L., Zhu, Z., Xiao, H., Redington, C. G., Ding, V. A., Stewart-Hester, T., Bai, Q., Dunlap, J., Wakefield, M. R., et al. (2018) · Medical Oncology · doi:10.1007/s12032-018-1236-y · Cited by 25
Wiedemann, G. M., Röhrle, N., Makeschin, M., Fesseler, J., Endres, S., Mayr, D. C., & Anz, D. (2019) · Pathology · doi:10.1016/j.pathol.2019.06.001 · Cited by 25
Cauli, A., Piga, M., Floris, A., & Mathieu, A. (2015) · ImmunoTargets and Therapy · doi:10.2147/itt.s62870 · Cited by 24
Suzuki, S., Umezu, Y., Saijo, Y., Satoh, G., Abe, Y., Satoh, K., & Nukiwa, T. (1998) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.185.223 · Cited by 24
Lin, L., Rayman, P. A., Pavicic, P. G., Tannenbaum, C. S., Hamilton, T. A., Montero, A. J., Ko, J. S., Gastman, B., Finke, J. H., Ernstoff, M. S., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2280-3 · Cited by 24
Diagnostic and prognostic value of serum IL-23 in colorectal cancer
El‐Essawi, D. F., Alkady, M. M., & Ibrahim, I. M. (2019) · Arab Journal of Gastroenterology · doi:10.1016/j.ajg.2019.05.002 · Cited by 24
Jiang, H. L., Zhang, T., Yan, M.-X., & Wu, W. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.07.30 · Cited by 24
Deplanque, G., Shabafrouz, K., & Obéid, M. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2000-4 · Cited by 22
IL23 and TGF-ß diminish macrophage associated metastasis in pancreatic carcinoma
Hussain, S. M., Reed, L. F., Krasnick, B. A., Miranda‐Carboni, G. A., Fields, R. C., Bi, Y., Elahi, A. H., Ajidahun, A. O., Dickson, P. V., Deneve, J. L., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24194-5 · Cited by 22
Innate lymphoid cells involve in tumorigenesis
Tian, Z., van Velkinburgh, J. C., Wu, Y., & Ni, B. (2015) · International Journal of Cancer · doi:10.1002/ijc.29443 · Cited by 20
Stanilov, N., Miteva, L. D., Jovchev, J. P., Cirovski, G., & Stanilova, S. A. (2014) · Apmis · doi:10.1111/apm.12288 · Cited by 20
Role of IL-23 signaling in the progression of premalignant oral lesions to cancer
Caughron, B., Yang, Y., & Young, M. R. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196034 · Cited by 19
Expression of IL-23R and IL-17 and the pathology and prognosis of urinary bladder carcinoma
Liu, J., Wang, L., Wang, T., & Wang, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.9145 · Cited by 19
IL-27 suppresses SKOV3 cells proliferation by enhancing STAT3 and inhibiting the Akt signal pathway
Zhang, Z., Zhou, B., Zhang, K., Song, Y., Zhang, L., & Xi, M. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.09.014 · Cited by 18
Rolvering, C., Zimmer, A. D., Ginolhac, A., Margue, C., Kirchmeyer, M., Servais, F., Hermanns, H. M., Hergovits, S., Nazarov, P. V., Nicot, N., et al. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.ma1217-495r · Cited by 17
Poly(I:C)-Mediated Death of Human Prostate Cancer Cell Lines Is Induced by Interleukin-27 Treatment
Kourko, O., Smyth, R., Cino, D., Seaver, K., Petes, C., Eo, S. Y., Basta, S., & Gee, K. (2019) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2018.0166 · Cited by 17
Chen, Z., Sakuishi, K., Xiao, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms8657 · Cited by 16
Li, X., Li, D., Shi, Q., Huang, X., & Ju, X. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10074 · Cited by 14
Liu, X., Sun, Y., Zheng, Y., Zhang, M., Jin, X., Kang, K., Wang, Y., Li, S., Zhang, H., Zhao, Q., et al. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000493298 · Cited by 13
RORC overexpression as a sign of Th17 lymphocytes accumulation in multiple myeloma bone marrow
Hmid, A. B., Selmi, O., Rekik, R., Lamari, H., Zamali, I., Ladeb, S., Safra, I., Othman, T. B., Romdhane, N. B., & Ahmed, M. B. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155210 · Cited by 12
Combined Effect of IL-12Rβ2 and IL-23R Expression on Prognosis of Patients with Laryngeal Cancer
Tao, Y., Tao, T., Gross, N. D., Peng, X., Li, Y., Huang, Z., Liu, L., Li, G., Chen, X., & Yang, J. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000494515 · Cited by 11
IL-23/IL-27 Ratio in Peripheral Blood of Patients with Breast Cancer.
Khodadadi, A., Razmkhah, M., Eskandari, A., Hosseini, A., Habibagahi, M., Ghaderi, A. A., & Jaberipour, M. (2014) · PubMed Central · Cited by 9
Correction to: IL-39 acts as a friend to pancreatic cancer
Manning, A. A., Zhao, L., Zhu, Z., Xiao, H., Redington, C. G., Ding, V. A., Stewart-Hester, T., Bai, Q., Dunlap, J., Wakefield, M. R., et al. (2019) · Medical Oncology · doi:10.1007/s12032-018-1244-y · Cited by 8
Li, Q., Sato, A., Shimozato, O., Shingyoji, M., Tada, Y., Tatsumi, K., Shimada, H., Hiroshima, K., & Tagawa, M. (2015) · Scandinavian Journal of Immunology · doi:10.1111/sji.12321 · Cited by 5
Baird, A., Leonard, J. M., Naicker, K. M., Kilmartin, L., O'Byrne, K. J., & Gray, S. G. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.10.003
Cited by
Inflammatory Processes in Alzheimer’s Disease—Pathomechanism, Diagnosis and Treatment: A Review
Twarowski, B., & Herbet, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076518 · Cited by 412
Mesenchymal stem/stromal cells in cancer therapy
Lan, T., Luo, M., & Wei, X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01208-w · Cited by 374
B Cell Function in the Tumor Microenvironment
Downs-Canner, S. M., Meier, J., Vincent, B. G., & Serody, J. S. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101220-015603 · Cited by 287
Liu, M., Hu, S., Yan, N., Popowski, K. D., & Cheng, K. (2024) · Nature Nanotechnology · doi:10.1038/s41565-023-01580-3 · Cited by 277
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders
Maskalenko, N. A., Zhigarev, D., & Campbell, K. S. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00413-7 · Cited by 256
Metadata
- Authors
- Mirlekar, B., & Pylayeva-Gupta, Y.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-01-06
- Volume
- 13
- Issue
- 2
- Pages
- 167
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3119125259
- Cited by
- 295
- References
- 197
- FWCI
- 15.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.